季節性情緒障礙治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球季節性情緒障礙治療市場價值為 8.216 億美元，預計 2025 年至 2034 年期間的複合年成長率為 4.7%。季節性情感障礙病例的增加推動了對有效、經濟且患者友善的治療方案的需求。 SAD 治療包括光療、抗憂鬱藥物、心理療法和創新干預措施，旨在控制由季節變化（尤其是在秋季和冬季）引發的情緒障礙。治療方法的進步，例如改進的光療設備和緩釋抗憂鬱藥，正在提高治療效果，促進市場成長。此外，人工智慧情緒追蹤應用程式和遠距精神病學平台等數位健康工具正在實現個人化治療計劃。這些將行為療法與生活方式改變相結合的綜合治療方法正得到越來越多的採用。這種整體方法不僅解決了根本原因，而且還增強了患者的整體健康。

市場按治療類型、疾病類型和最終用途進行細分。根據治療類型，市場包括藥物和治療部分。 2024 年，藥物部門的銷售額為 5.297 億美元，包括選擇性血清素再攝取抑制劑 (SSRI)、去甲腎上腺素-多巴胺再攝取抑制劑 (NDRI)、單胺氧化酶抑制劑 (MAOI) 和其他藥物。氟西汀和舍曲林等 SSRI 類藥物透過調節生化平衡來控制情緒，在控制憂鬱症狀方面發揮著至關重要的作用。緩釋配方等創新技術提高了患者的依從性並減少了副作用。此外，將抗憂鬱藥物與褪黑激素受體激動劑等補充療法相結合，可實現治療選擇的多樣化並支持市場擴張。由藥物基因組學推動的個人化醫療提高了治療效果並進一步推動了市場的發展。

根據疾病類型，市場分為秋冬季 SAD 和春夏季 SAD。由於在白天時間較短的時期 SAD 盛行率較高，秋冬季 SAD 細分市場在 2024 年佔據了 81.6% 的市場。日照減少會擾亂晝夜節律和血清素的產生，導致憂鬱症狀。該領域受益於先進的光療設備、改進的抗憂鬱藥物以及針對這些季節性情緒觸發因素而客製化的認知行為療法的開發。人們對季節性情緒障礙的認知不斷提高以及聯合療法的日益普及有助於該領域繼續佔據主導地位。

根據最終用途，市場分為醫院、專科診所、家庭護理機構和其他最終用戶。專科診所佔據了相當大的市場佔有率，預計到 2034 年將達到 5.163 億美元。這些診所提供具有先進診斷和治療程序的專科護理，滿足尋求光療和藥物干預等客製化治療的患者的需求。專科診所利用情緒追蹤技術和遠距精神病學服務提供全面護理，這有助於其日益突出的地位。人們對心理健康的認知不斷提高、全科醫生的轉診以及患者對專科護理的偏好正在推動專科診所的發展。

在北美，美國季節性情感障礙治療市場預計將以 4.7% 的複合年成長率成長，到 2034 年達到 5.121 億美元。推動這一成長的因素包括心理健康意識的提高、季節性情感障礙的高盛行率以及先進醫療保健基礎設施的可用性。光療設備的廣泛採用、精神健康報銷政策以及遠距精神病學平台的進步也增強了早期診斷並改善了治療結果，從而支持了該地區的市場成長。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 提高對精神健康障礙和季節性情感障礙的認知
    • 先進治療方式的採用率不斷上升
    • 拓展藥品和治療產品的網路零售通路
  • 產業陷阱與挑戰
    • 光療設備和治療服務成本高昂
    • 發展中地區對季節性情感障礙的認知有限
• 成長潛力分析
• 監管格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按治療類型，2021-2034

• 主要趨勢
• 藥物
  • 選擇性血清素再攝取抑制劑（SSRI）
  • 去甲腎上腺素多巴胺再攝取抑制劑 (NDRI)
  • 單胺氧化酶抑制劑（MAOI）
  • 其他藥物類型
• 治療
  • 光療法
  • 心理治療

第6章：市場估計與預測：依疾病類型，2021-2034 年

• 主要趨勢
• 秋冬季節 SAD
• 春夏季節 SAD

第7章：市場估計與預測：依最終用途，2021-2034

• 主要趨勢
• 醫院
• 專科診所
• 居家照護環境
• 其他最終用途

第8章：市場估計與預測：按地區，2021-2034

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Amen Clinics
• Bausch Health Companies
• Cleveland Clinic
• Eli Lilly and Company
• GlaxoSmithKline
• Henry Schein
• Johnson & Johnson (Janssen Pharmaceuticals)
• Mayo Clinic
• Novartis
• Otsuka Pharmaceutical
• Pfizer
• Sanofi
• Teva Pharmaceuticals
• The SunBox Company
• Verilux
• Viatris (Mylan)

The Global Seasonal Affective Disorder Therapeutics Market was valued at USD 821.6 million in 2024 and is anticipated to grow at a 4.7% CAGR from 2025 to 2034. Rising cases of SAD are driving demand for effective, affordable, and patient-friendly treatment options. SAD treatments include light therapy, antidepressants, psychotherapy, and innovative interventions aimed at managing mood disorders triggered by seasonal changes, particularly during fall and winter. Advancements in treatment methods, such as improved light therapy devices and extended-release antidepressants, are increasing the efficacy of therapies, contributing to market growth. Additionally, digital health tools such as AI-powered mood tracking apps and telepsychiatry platforms are enabling personalized treatment plans. These combined treatment approaches, which integrate behavioral therapy with lifestyle changes, are witnessing growing adoption. This holistic approach not only addresses the underlying causes but also enhances overall patient well-being.

The market is segmented by treatment type, disorder type, and end use. Based on treatment type, the market includes medication and therapy segments. The medication segment, which accounted for USD 529.7 million in 2024, includes selective serotonin reuptake inhibitors (SSRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), monoamine oxidase inhibitors (MAOIs), and other medications. SSRIs, such as fluoxetine and sertraline, play a vital role in managing depressive symptoms by regulating mood through biochemical balance. Innovations such as extended-release formulations improve patient adherence and reduce side effects. Furthermore, combining antidepressants with complementary treatments, such as melatonin receptor agonists, is diversifying treatment options and supporting market expansion. Personalized medicine, driven by pharmacogenomics, enhances treatment efficacy and further propels the market.

By disorder type, the market is divided into fall & winter SAD and spring & summer SAD. The fall & winter SAD segment held an 81.6% market share in 2024 due to the higher prevalence of SAD during periods with shorter daylight hours. Reduced sunlight disrupts circadian rhythms and serotonin production, leading to depressive symptoms. This segment benefits from the development of advanced light therapy devices, improved antidepressants, and cognitive-behavioral therapies tailored to address these seasonal mood triggers. Increased awareness of seasonal mood disorders and the growing adoption of combination therapies contribute to the continued dominance of this segment.

By end use, the market is categorized into hospitals, specialty clinics, homecare settings, and other end users. Specialty clinics accounted for a significant market share and are expected to reach USD 516.3 million by 2034. These clinics offer specialized care with advanced diagnostic and treatment procedures, catering to patients seeking tailored therapies such as light therapy and pharmacological interventions. Specialty clinics provide integrated care using mood-tracking technologies and telepsychiatry services, contributing to their growing prominence. Increased awareness of mental health, referrals from general practitioners, and patient preference for specialized care are driving the growth of specialty clinics.

In North America, the US seasonal affective disorder therapeutics market is projected to grow at a 4.7% CAGR, reaching USD 512.1 million by 2034. Factors contributing to this growth include rising mental health awareness, high prevalence of SAD, and the availability of advanced healthcare infrastructure. Widespread adoption of light therapy devices, reimbursement policies for mental health, and advancements in telepsychiatry platforms also enhance early diagnosis and improve treatment outcomes, supporting market growth in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness of mental health disorders and seasonal affective disorder
    • 3.2.1.2 Rising adoption of advanced treatment modalities
    • 3.2.1.3 Expanding online retail channels for pharmaceuticals and therapy products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of light therapy devices and treatment services
    • 3.2.2.2 Limited awareness in developing regions about seasonal affective disorder
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Selective serotonin reuptake inhibitors (SSRI)
  • 5.2.2 Norepinephrine-dopamine reuptake inhibitor (NDRI)
  • 5.2.3 Monoamine oxidase inhibitor (MAOI)
  • 5.2.4 Other drug types
• 5.3 Therapy
  • 5.3.1 Light therapy
  • 5.3.2 Psychotherapy

Chapter 6 Market Estimates and Forecast, By Disorder Type, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Fall & winter SAD
• 6.3 Spring & summer SAD

Chapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Homecare setting
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Amen Clinics
• 9.3 Bausch Health Companies
• 9.4 Cleveland Clinic
• 9.5 Eli Lilly and Company
• 9.6 GlaxoSmithKline
• 9.7 Henry Schein
• 9.8 Johnson & Johnson (Janssen Pharmaceuticals)
• 9.9 Mayo Clinic
• 9.10 Novartis
• 9.11 Otsuka Pharmaceutical
• 9.12 Pfizer
• 9.13 Sanofi
• 9.14 Teva Pharmaceuticals
• 9.15 The SunBox Company
• 9.16 Verilux
• 9.17 Viatris (Mylan)